New drug combo for Hard-to-Treat cancers shows early promise but trial halted

NCT ID NCT06560632

Terminated Disease control Sponsor: Repare Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are not available, but it aimed to explore a potential new option for people with few choices left.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RP-3467 (a Polθ inhibitor) and olaparib (a PARP inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It was terminated, so results may be limited. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma castration-resistant prostate carcinoma fallopian tube cancer neoplasm ovarian carcinoma pancreatic adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

# 1001, The University of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
# 1004, Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
# 1008, Columbia University

New York, New York, 10032, United States
# 1011, The Washington University

St Louis, Missouri, 63130, United States
# 1025, The University of California

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.